Companies › Ensysce Biosciences
2 active drug programs in 15 registered trials: 8 Phase 4, 4 Phase 1, 3 Phase 3; Other, Neurology, Infectious disease; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Oxycodone (PF614) Mu opioid receptor agonist | OPRM1 | Phase 3 | Postoperative Pain, Acute; Pharmacokinetics; Laparoscopic Hysterectomy; Liquid Oxycodone … | Nov 2026 |
| Nafamostat Mesylate Serine protease inhibitor | – | Phase 1 | Pharmacokinetics | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06690307 | Oxycodone (PF614) | Phase 4 | Laparoscopic Hysterectomy | Other | Dec 2025 |
| NCT06602271 | Oxycodone (PF614) | Phase 3 | Postoperative Pain, Acute | Neurology | Nov 2026 |
| NCT03054831 | Oxycodone (PF614) | Phase 4 | Liquid Oxycodone | Other | Dec 2026 |
| NCT06500793 | Oxycodone (PF614) | Phase 1 | Pharmacokinetics | Other | Dec 2026 |
| NCT06500793 | Nafamostat Mesylate | Phase 1 | Pharmacokinetics | Other | Dec 2026 |
| NCT07323914 | Oxycodone (PF614) | Phase 3 | Alzheimer Disease | Neurology | Jan 2027 |
| NCT05722002 | Oxycodone (PF614) | Phase 4 | Surgery | Other | Feb 2027 |
| NCT07773155 | Oxycodone (PF614) | Phase 4 | Surgery, Upper Extremity | Other | Feb 2027 |
| NCT02044497 | Oxycodone (PF614) | Phase 4 | Pediatric Surgical Patient | Other | May 2027 |
| NCT06671002 | Oxycodone (PF614) | Phase 4 | Surgery | Other | Oct 2027 |
| NCT03759028 | Oxycodone (PF614) | Phase 4 | Supracondylar Humerus Fracture | Other | Dec 2027 |
| NCT06186141 | Oxycodone (PF614) | Phase 4 | Patient-Controlled Analgesia | Other | Dec 2027 |
| NCT04659317 | Oxycodone (PF614) | Phase 3 | Pain | Other | Dec 2028 |
| NCT06757140 | Oxycodone (PF614) | Phase 1 | Drug Interactions | Other | Jan 2029 |
| NCT07824258 | Oxycodone (PF614) | Phase 1 | Vasectomy | Infectious disease | Dec 2030 |
Cash of $1m on 2026-06-30; operating cash outflow about $11m a year; runway about 1 months at that burn, to Jul 2026; 0 of 3 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Inventage Lab. Trevi Therapeutics Shionogi Currax Pharmaceuticals AgelessRx ReacX Pharmaceuticals Akyso Therapeutics Boulder Care Adneuris Therapeutics Alkermes
Avenue Therapeutics Aligos Therapeutics Atea Pharmaceuticals Shanghai Ark Biopharmaceutical Scholar Rock
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.